ArticleExperimental & molecular medicine2026
Generation of the functionally enhanced proximal tubular cells from human iPSC-derived kidney organoids.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Human renal proximal tubular epithelial cells (RPPTCs) are crucial for exploring the molecular and cellular mechanisms underlying the pathophysiology of kidney injuries. In this study, we generated the functionally enhanced kidney organoid-derived proximal tubule cells (FEKOPTCs) from human induced pluripotent stem cells. Heparan sulfate proteoglycans and transforming growth factor-β receptor inhibitor enhanced the functionality of PTCs isolated from the kidney organoids of which the vascularization and maturation were improved by heparan sulfate proteoglycans and vascular endothelial growth factor. FEKOPTCs showed significantly enhanced epithelial barrier function, polarization state, and transporter function, compared with primary human RPTECs, which led to improve the function of drug uptake. Transcriptomic characterization of FEKOPTCs revealed high similarity to PTCs of native human adult kidney. FEKOPTCs-on-chip are more sensitive predictors than RPTECs-on-chip for nephrotoxicity testing. By using CRISPR-Cas9 genetic mutation of alpha-galactosidase A, the causative gene of Fabry disease, alpha-galactosidase A-mutant FEKOPTCs, recapitulated the functional phenotype of Fabry disease. When FEKOPTCs were transplanted into the kidney parenchyma of NOD-SCID mice, they reassembled and regenerated proximal tubular structures with intact lumens and functional transporters. Taken together, our results suggest that FEKOPTCs are functionally enhanced PTCs and can be applied for nephrotoxicity testing, disease modeling, and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.